Abstract
Diabetes is a major risk factor for left ventricular dysfunction with cardiac and renal fibrosis. C-type natriuretic peptide (CNP) is a 22 amino-acid peptide produced mainly in the cardiac endothelium with potent cardiac unloading, anti-fibrotic and antihypertensive effects, but minimal renal actions. Using this knowledge we designed a natriuretic peptide CBA-NP by fusing a 6 AA sequence (KVLRRH) from BNP to the C-terminus and a 5 AA sequence (RMDRI) from ANP to the N-terminus of CNP to enhance beneficial renal effects while maintaining CNP’s inherent cardioprotective properties.
Highlights
Diabetes is a major risk factor for left ventricular dysfunction with cardiac and renal fibrosis
Using three groups of six male Wistar rats, one dose of streptozotocin was administered to induce diabetes
LV interstitial and perivascular fibrosis percentage was significantly reduced in the CBA-NP treated group (3.27 to 1.80 and 3.87 to 1.77) as compared to the diabetic control
Summary
Diabetes is a major risk factor for left ventricular dysfunction with cardiac and renal fibrosis. Treatment with CBA-NP a novel chimeric natriuretic peptide attenuates cardiorenal fibrosis and improves diastolic dysfunction in diabetic rat model Syed Ameenuddin, Elise A Oehler, John C Burnett Jr, Horng H Chen* From 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications Halle, Germany.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
